Janus Henderson Global Life Sciences D (JNGLX)

Fund Assets	6.03B
Expense Ratio	0.81%
Min. Investment	$2,500
Turnover	30.00%
Dividend (ttm)	0.36
Dividend Yield	0.42%
Dividend Growth	47.03%
Payout Frequency	Annual
Ex-Dividend Date	Dec 5, 2025

Previous Close	86.21
YTD Return	6.45%
1-Year Return	23.69%
5-Year Return	47.72%
52-Week Low	73.00
52-Week High	94.22
Beta (5Y)	0.79
Holdings	98
Inception Date	Dec 31, 1998

About JNGLX

Janus Henderson Global Life Sciences Fund Class D is an open-end mutual fund that targets long-term capital growth by investing primarily in equities of companies within the global life sciences sector. The fund focuses on a diverse range of healthcare segments, including pharmaceuticals, biotechnology, medical devices, and healthcare services, seeking firms that address unmet medical needs or contribute to healthcare efficiency. Its investment approach is global and diversified, spanning companies of varying market capitalizations and geographies, with at least 80% of assets invested in life sciences-oriented companies and up to 20% in developing markets. The fund employs fundamental, bottom-up analysis to identify growth opportunities and benchmarks its performance against the MSCI World Health Care Index and the S&P 500 Index. The portfolio is managed by an experienced team with deep sector expertise, aiming to maintain a balance across healthcare subsectors. Notable holdings typically include leading global healthcare companies such as Eli Lilly, UnitedHealth Group, and Novo Nordisk. The fund’s role is to provide investors with targeted exposure to innovation and structural growth within the life sciences and healthcare industries, making it a specialized option for sector-focused investing within the broader equity markets.

• Fund Family: Janus Henderson
• Category: Health
• Performance Rating: High
• Risk Rating: Average
• Stock Exchange: NASDAQ
• Ticker Symbol: JNGLX
• Share Class: Class D
• Index: MSCI World/Health Care NR

Performance

JNGLX had a total return of 23.69% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.33%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
JFNNX	Class N	0.68%
JFNIX	Class I	0.78%
JAGLX	Class T	0.92%
JFNAX	Class A	1.00%

Top 10 Holdings

42.22% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	9.05%
Johnson & Johnson	JNJ	7.48%
AbbVie Inc.	ABBV	4.63%
UnitedHealth Group Incorporated	UNH	4.33%
AstraZeneca PLC	AZN	3.50%
Thermo Fisher Scientific Inc.	TMO	2.92%
Novartis AG ADR	NVSN.MX	2.78%
Roche Holding AG	ROP	2.63%
argenx SE	ARGX	2.55%
Abbott Laboratories	ABT	2.36%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 5, 2025	$3.69607	Dec 5, 2025
Dec 6, 2024	$3.96273	Dec 6, 2024
Dec 7, 2023	$2.94435	Dec 7, 2023
Dec 20, 2022	$0.17114	Dec 20, 2022
Dec 20, 2021	$6.81696	Dec 20, 2021
Dec 17, 2020	$5.56759	Dec 17, 2020

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 3, 2026

Data Sources Report a data error